CRISPR Therapeutics - CRSP Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $76.29
Forecasted Upside: 40.41%
Number of Analysts: 16
Breakdown:
2 Sell Ratings
6 Hold Ratings
8 Buy Ratings
0 Strong Buy Ratings

^$54.33 As of 04/19/2024 03:47 PM ET

▼ -1.83 (-3.26%)

1 month | 3 months | 12 months

Get New CRISPR Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for CRSP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRSP

^$76.29

▲ +40.41% Upside Potential

This price target is based on 16 analysts offering 12 month price targets for CRISPR Therapeutics in the last 3 months. The average price target is $76.29, with a high forecast of $112.00 and a low forecast of $30.00. The average price target represents a 40.41% upside from the last price of $54.33.

Current Consensus is Hold

The current consensus among 16 investment analysts is to hold stock in CRISPR Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

10/26/2022

0 strong buy ratings
8 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

1/24/2023

0 strong buy ratings
8 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

4/24/2023

0 strong buy ratings
8 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

7/23/2023

0 strong buy ratings
8 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

10/21/2023

0 strong buy ratings
8 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

1/19/2024

0 strong buy ratings
8 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

3/19/2024

0 strong buy ratings
8 buy ratings
6 hold ratings
2 sell ratings

Ratings as of

4/18/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/18/2024	Citigroup	Boost Target	Buy ➝ Buy	$88.00 ➝ $89.00	Low
4/11/2024	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$90.00	Low
3/6/2024	Mizuho	Boost Target	Buy ➝ Buy	$82.00 ➝ $99.00	Low
2/26/2024	Morgan Stanley	Boost Target	Underweight ➝ Underweight	$46.00 ➝ $48.00	Low
2/22/2024	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$57.00 ➝ $66.00	Low
2/22/2024	Wells Fargo & Company	Boost Target	Equal Weight ➝ Equal Weight	$55.00 ➝ $70.00	Low
2/22/2024	Barclays	Boost Target	Equal Weight ➝ Equal Weight	$61.00 ➝ $80.00	Low
2/22/2024	Chardan Capital	Boost Target	Buy ➝ Buy	$110.00 ➝ $112.00	Low
2/21/2024	Needham & Company LLC	Boost Target	Buy ➝ Buy	$88.00 ➝ $90.00	Low
2/15/2024	Wolfe Research	Initiated Coverage	Peer Perform		Low
12/11/2023	Royal Bank of Canada	Boost Target	Sector Perform ➝ Sector Perform	$50.00 ➝ $57.00	Low
12/11/2023	Barclays	Boost Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $61.00	Low
12/11/2023	Needham & Company LLC	Boost Target	Buy ➝ Buy	$85.00 ➝ $88.00	Low
12/11/2023	JMP Securities	Boost Target	Market Outperform ➝ Market Outperform	$74.00 ➝ $80.00	Low
12/11/2023	TD Cowen	Downgrade	Market Perform ➝ Underperform	$30.00	Low
12/8/2023	Mizuho	Reiterated Rating	Buy ➝ Buy	$82.00	Low
12/8/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy		Low
12/5/2023	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$74.00	Low
11/13/2023	Morgan Stanley	Lower Target	Underweight ➝ Underweight	$43.00 ➝ $42.00	Low
11/7/2023	Royal Bank of Canada	Lower Target	Sector Perform ➝ Sector Perform	$55.00 ➝ $50.00	Low
11/7/2023	Needham & Company LLC	Lower Target	Buy ➝ Buy	$88.00 ➝ $85.00	Low
10/30/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$88.00	Low
10/17/2023	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral		Low
9/26/2023	Mizuho	Initiated Coverage	Buy	$82.00	Low
8/17/2023	Citigroup	Upgrade	Neutral ➝ Buy	$70.00	Low
8/14/2023	Morgan Stanley	Boost Target	Underweight ➝ Underweight	$42.00 ➝ $43.00	Low
8/10/2023	Oppenheimer	Reiterated Rating	Outperform ➝ Outperform	$102.00	Low
8/8/2023	Credit Suisse Group	Boost Target	Neutral ➝ Neutral	$62.00 ➝ $63.00	Low
8/8/2023	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$88.00	Low
8/7/2023	Chardan Capital	Lower Target	Buy ➝ Buy	$123.00 ➝ $110.00	Low
7/25/2023	JMP Securities	Reiterated Rating	Market Outperform ➝ Market Outperform	$74.00	Low
6/9/2023	JMP Securities	Boost Target		$70.00 ➝ $74.00	Low
6/1/2023	Barclays	Boost Target		$61.00 ➝ $64.00	Low
5/30/2023	William Blair	Initiated Coverage	Outperform	$75.00	Low
5/23/2023	Citigroup	Boost Target		$55.00 ➝ $70.00	Low
5/9/2023	VNET Group	Reiterated Rating	Reiterates		Low
5/9/2023	Stifel Nicolaus	Lower Target		$69.00 ➝ $64.00	Low
4/20/2023	Needham & Company LLC	Reiterated Rating	Buy	$82.00	Low
4/17/2023	EF Hutton Acquisition Co. I	Reiterated Rating	Buy	$75.00	Low
4/17/2023	JMP Securities	Reiterated Rating	Market Outperform	$70.00	Low
4/13/2023	Cantor Fitzgerald	Initiated Coverage	Overweight	$72.00	Low
4/3/2023	EF Hutton Acquisition Co. I	Reiterated Rating	Buy	$75.00	Low
3/21/2023	Sanford C. Bernstein	Initiated Coverage	Market Perform	$44.00	Low
3/17/2023	Citigroup	Lower Target		$63.00 ➝ $55.00	Low
3/17/2023	Bryan, Garnier & Co	Initiated Coverage	Buy	$70.00	Low
3/6/2023	Robert W. Baird	Initiated Coverage	Neutral	$46.00	Low
2/27/2023	Morgan Stanley	Boost Target	Underweight	$37.00 ➝ $39.00	Low
2/27/2023	JMP Securities	Reiterated Rating	Market Outperform	$70.00	Low
2/23/2023	Oppenheimer	Lower Target	Outperform	$110.00 ➝ $102.00	Low
2/22/2023	Needham & Company LLC	Lower Target	Buy	$122.00 ➝ $82.00	Low
2/22/2023	EF Hutton Acquisition Co. I	Reiterated Rating	Buy	$75.00	Low
2/22/2023	Credit Suisse Group	Lower Target	Neutral	$78.00 ➝ $65.00	Low
2/22/2023	Chardan Capital	Lower Target	Buy	$153.00 ➝ $123.00	Low
1/19/2023	JMP Securities	Lower Target	Market Outperform	$100.00 ➝ $70.00	Low
1/5/2023	EF Hutton Acquisition Co. I	Initiated Coverage	Buy	$75.00	Low
11/23/2022	Citigroup	Lower Target	Neutral	$83.00 ➝ $63.00	Low
11/7/2022	SVB Leerink	Boost Target	Outperform	$75.00 ➝ $76.00	Low
11/2/2022	Royal Bank of Canada	Lower Target	Sector Perform	$79.00 ➝ $70.00	Low
11/2/2022	Barclays	Lower Target		$88.00 ➝ $61.00	Low
11/2/2022	Credit Suisse Group	Lower Target		$90.00 ➝ $78.00	Low
10/11/2022	Morgan Stanley	Initiated Coverage	Underweight	$37.00	Low
8/9/2022	Stifel Nicolaus	Boost Target		$55.00 ➝ $69.00	Low
8/9/2022	Chardan Capital	Lower Target	Buy	$164.00 ➝ $154.00	Low
8/9/2022	Royal Bank of Canada	Lower Target	Sector Perform	$85.00 ➝ $79.00	Low
8/9/2022	Credit Suisse Group	Boost Target	Neutral	$74.00 ➝ $90.00	Low
8/9/2022	Barclays	Downgrade	Overweight ➝ Equal Weight	$99.00 ➝ $88.00	Low
8/8/2022	SVB Leerink	Lower Target	Outperform	$112.00 ➝ $107.00	Low
8/2/2022	Citigroup	Boost Target	Neutral	$53.00 ➝ $83.00	Low
6/23/2022	Oppenheimer	Lower Target	Outperform	$150.00 ➝ $122.00	Low
6/22/2022	Stifel Nicolaus	Reiterated Rating	Hold	$57.00 ➝ $55.00	Low
6/22/2022	Chardan Capital	Lower Target	Buy	$168.00 ➝ $164.00	Low
6/22/2022	Piper Sandler	Boost Target	Overweight	$115.00 ➝ $121.00	Low
6/16/2022	BMO Capital Markets	Initiated Coverage	Outperform	$98.00	High
6/13/2022	Stifel Nicolaus	Boost Target		$52.00 ➝ $57.00	High
5/24/2022	The Goldman Sachs Group	Lower Target	Neutral	$52.00 ➝ $46.00	Low
5/23/2022	Piper Sandler	Lower Target	Overweight	$180.00 ➝ $115.00	Medium
5/17/2022	Citigroup	Lower Target	Neutral	$64.00 ➝ $53.00	N/A
5/13/2022	Needham & Company LLC	Lower Target		$170.00 ➝ $122.00	Low
5/11/2022	Oppenheimer	Lower Target		$172.00 ➝ $150.00	High
5/10/2022	Royal Bank of Canada	Lower Target		$95.00 ➝ $85.00	High
5/10/2022	Barclays	Lower Target		$107.00 ➝ $99.00	High
5/10/2022	Chardan Capital	Lower Target		$171.00 ➝ $168.00	High
4/28/2022	Credit Suisse Group	Initiated Coverage	Neutral	$78.00	High
3/15/2022	Citigroup	Lower Target	Neutral	$90.00 ➝ $64.00	Medium
2/17/2022	The Goldman Sachs Group	Lower Target	Neutral	$179.00 ➝ $87.00	High
2/16/2022	Stifel Nicolaus	Lower Target		$64.00	Low
2/16/2022	Truist Financial	Reiterated Rating	Buy	$220.00	High
2/16/2022	Royal Bank of Canada	Lower Target	Sector Perform	$117.00 ➝ $95.00	High
2/16/2022	Barclays	Lower Target		$148.00 ➝ $107.00	High
2/16/2022	SVB Leerink	Lower Target	Outperform	$126.00 ➝ $120.00	Medium
2/14/2022	Brookline Capital Acquisition	Initiated Coverage	Buy	$143.00	High
2/14/2022	Brookline Capital Management	Reiterated Rating	Buy	$143.00	High
12/6/2021	Cowen	Initiated Coverage	Market Perform		High
11/4/2021	Oppenheimer	Lower Target	Outperform	$185.00 ➝ $172.00	Low
11/4/2021	Barclays	Lower Target	Overweight	$160.00 ➝ $148.00	High
10/19/2021	SVB Leerink	Initiated Coverage	Outperform	$126.00	Medium
10/13/2021	Chardan Capital	Reiterated Rating	Buy	$171.00	Low
10/13/2021	Stifel Nicolaus	Lower Target	Hold	$139.00 ➝ $101.00	High
10/13/2021	William Blair	Reiterated Rating	Buy		Medium
7/30/2021	Chardan Capital	Lower Target	Buy	$175.00 ➝ $171.00	High
7/7/2021	Chardan Capital	Reiterated Rating	Buy		Medium
6/14/2021	Citigroup	Upgrade	Sell ➝ Neutral	$55.00 ➝ $132.00	Low
5/13/2021	Evercore ISI	Upgrade	Outperform		High
4/21/2021	Barclays	Boost Target	Overweight	$140.00 ➝ $160.00	High
4/21/2021	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$172.00	Medium
3/4/2021	JMP Securities	Initiated Coverage	Outperform	$160.00	High
3/1/2021	Barclays	Boost Target	Overweight	$113.00 ➝ $140.00	Low
2/28/2021	Barclays	Reiterated Rating	Buy		Low
2/17/2021	The Goldman Sachs Group	Lower Target	Neutral	$193.00 ➝ $189.00	Medium
2/17/2021	Oppenheimer	Boost Target	Outperform	$165.00 ➝ $187.00	Low
2/17/2021	Chardan Capital	Boost Target	Buy	$166.00 ➝ $175.00	Low
2/17/2021	Needham & Company LLC	Reiterated Rating	Buy		Low
1/12/2021	Truist Financial	Boost Target		$170.00 ➝ $210.00	Low
12/10/2020	Chardan Capital	Boost Target	Buy	$110.00 ➝ $166.00	High
12/10/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold		High
12/10/2020	Needham & Company LLC	Boost Target	Buy	$105.00 ➝ $170.00	Medium
12/10/2020	Piper Sandler	Boost Target	Overweight	$107.00 ➝ $180.00	Medium
12/7/2020	Stifel Nicolaus	Boost Target	Hold ➝ Positive	$91.00 ➝ $145.00	High
12/7/2020	Oppenheimer	Boost Target	Outperform	$105.00 ➝ $155.00	High
12/7/2020	Roth Capital	Boost Target	Buy	$115.00 ➝ $170.00	High
12/7/2020	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$102.63 ➝ $145.00	Low
10/30/2020	Raymond James	Reiterated Rating	Sell		High
10/29/2020	Piper Sandler	Lower Target	Overweight	$128.00 ➝ $107.00	Medium
10/22/2020	Royal Bank of Canada	Initiated Coverage	Sector Perform	$110.00 ➝ $110.00	Medium
10/22/2020	Chardan Capital	Boost Target	Positive ➝ Buy	$100.00 ➝ $110.00	High
10/21/2020	Stifel Nicolaus	Boost Target	Hold	$75.00 ➝ $93.00	Medium
10/21/2020	Roth Capital	Boost Target	Buy	$105.00 ➝ $115.00	High
10/21/2020	Piper Sandler	Boost Target	Overweight	$104.00 ➝ $128.00	High
10/5/2020	Bank of America	Initiated Coverage	Buy	$110.00 ➝ $110.00	High
8/5/2020	Citigroup	Reiterated Rating	Sell		Low
7/28/2020	Wells Fargo & Company	Boost Target	Overweight	$95.00 ➝ $110.00	High
7/28/2020	Chardan Capital	Boost Target	Buy	$72.50 ➝ $100.00	High
7/28/2020	Needham & Company LLC	Boost Target	Buy	$84.00 ➝ $105.00	Medium
7/28/2020	William Blair	Reiterated Rating	Buy		Medium
7/28/2020	Barclays	Boost Target	Positive ➝ Overweight	$65.00 ➝ $102.00	High
7/27/2020	Oppenheimer	Initiated Coverage	Buy	$89.00 ➝ $105.00	Medium
7/14/2020	SunTrust Banks	Initiated Coverage	Buy	$140.00	Low
6/23/2020	Oppenheimer	Boost Target	Outperform	$80.00 ➝ $89.00	High
6/19/2020	Piper Sandler	Reiterated Rating	Overweight	$104.00	High
6/19/2020	Roth Capital	Boost Target	Buy	$100.00 ➝ $105.00	Medium
6/12/2020	Piper Sandler	Reiterated Rating	Buy	$104.00	Medium
6/12/2020	Chardan Capital	Reiterated Rating	Buy	$72.50	Medium
6/12/2020	Needham & Company LLC	Initiated Coverage	Buy	$84.00	Medium
6/12/2020	Oppenheimer	Initiated Coverage	Buy	$80.00	Low
5/31/2020	Chardan Capital	Reiterated Rating	Buy		Medium
5/6/2020	Chardan Capital	Reiterated Rating	Buy		Medium
4/29/2020	Needham & Company LLC	Initiated Coverage	Buy	$84.00	High
4/28/2020	William Blair	Reiterated Rating	Buy		High
4/1/2020	Piper Sandler	Reiterated Rating	Buy	$104.00	Low
3/4/2020	Stifel Nicolaus	Initiated Coverage	Hold	$52.00	Low
3/4/2020	Citigroup	Boost Target	Sell	$28.00 ➝ $31.00	Medium
2/13/2020	Piper Sandler	Reiterated Rating	Buy	$104.00	High
2/13/2020	Chardan Capital	Reiterated Rating	Buy	$72.50	High
2/13/2020	William Blair	Reiterated Rating	Buy		High
1/30/2020	Chardan Capital	Reiterated Rating	Buy		Medium
12/23/2019	Needham & Company LLC	Reiterated Rating	Buy	$84.00	High
12/16/2019	Piper Sandler Companies	Reiterated Rating	Buy	$104.00	Low
12/6/2019	Wells Fargo & Company	Reiterated Rating	Buy		Low
11/26/2019	Piper Sandler Companies	Reiterated Rating	Buy	$104.00	Medium
11/25/2019	Oppenheimer	Boost Target	Outperform	$65.00 ➝ $80.00	Low
11/19/2019	Roth Capital	Boost Target		$65.00 ➝ $100.00	High
11/19/2019	Piper Sandler Companies	Boost Target	Buy	$100.00 ➝ $107.00	High
11/19/2019	Wells Fargo & Company	Reiterated Rating	Buy		High
11/19/2019	William Blair	Upgrade	Market Perform ➝ Outperform		High
11/19/2019	The Goldman Sachs Group	Boost Target	Positive ➝ Neutral	$52.00 ➝ $75.00	High
11/18/2019	Chardan Capital	Reiterated Rating	Buy	$72.50	High
11/12/2019	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$65.00	High
10/21/2019	Chardan Capital	Set Target	Buy	$72.50	Low
10/21/2019	Piper Sandler Companies	Reiterated Rating	Overweight		High
10/15/2019	Chardan Capital	Reiterated Rating	Buy	$72.50	Low
8/1/2019	Jefferies Financial Group	Initiated Coverage	Buy ➝ Buy	$64.00	Low
7/31/2019	Needham & Company LLC	Reiterated Rating	Buy	$62.00	Low
7/30/2019	Roth Capital	Boost Target		$50.00 ➝ $65.00	Medium
7/30/2019	Barclays	Boost Target	Overweight	$59.00 ➝ $62.00	Medium
7/30/2019	BTIG Research	Boost Target	Buy ➝ Positive	$51.00 ➝ $59.00	Medium
7/30/2019	William Blair	Reiterated Rating	Hold		Medium
6/10/2019	Roth Capital	Initiated Coverage	Buy	$50.00	Medium
6/7/2019	Chardan Capital	Set Target	Buy	$73.00	High
5/1/2019	Needham & Company LLC	Reiterated Rating	Buy	$62.00	Medium
4/22/2019	BTIG Research	Boost Target	Buy	$30.00 ➝ $33.00	Medium

(Data available from 4/19/2019 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

13 very positive mentions
6 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/22/2023

11 very positive mentions
10 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

10/22/2023

17 very positive mentions
17 positive mentions
5 negative mentions
1 very negative mentions

Mentions as of

11/21/2023

21 very positive mentions
22 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

12/21/2023

15 very positive mentions
25 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

1/20/2024

22 very positive mentions
27 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/19/2024

36 very positive mentions
29 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

3/20/2024

18 very positive mentions
37 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

4/19/2024

Current Sentiment

Recent Stories by Sentiment

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Today's Range

Now: $54.33

$54.33

$57.50

50 Day Range

MA: $73.51

$55.56

$89.12

52 Week Range

Now: $54.33

$37.55

$91.10

Volume

1,161,339 shs

Average Volume

1,836,015 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of CRISPR Therapeutics?: The following Wall Street research analysts have issued research reports on CRISPR Therapeutics in the last twelve months: Barclays PLC, Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Credit Suisse Group AG, JMP Securities, Mizuho, Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Royal Bank of Canada, Stifel Nicolaus, StockNews.com, TD Cowen, TheStreet, Truist Financial Co., VNET Group, Inc., Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for CRSP.
What is the current price target for CRISPR Therapeutics?: 14 Wall Street analysts have set twelve-month price targets for CRISPR Therapeutics in the last year. Their average twelve-month price target is $76.29, suggesting a possible upside of 35.1%. Chardan Capital has the highest price target set, predicting CRSP will reach $112.00 in the next twelve months. TD Cowen has the lowest price target set, forecasting a price of $30.00 for CRISPR Therapeutics in the next year.
View the latest price targets for CRSP.
What is the current consensus analyst rating for CRISPR Therapeutics?: CRISPR Therapeutics currently has 2 sell ratings, 6 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CRSP, but not buy more shares or sell existing shares.
View the latest ratings for CRSP.
What other companies compete with CRISPR Therapeutics?: Other companies that are similar to CRISPR Therapeutics include Halozyme Therapeutics, Krystal Biotech, Immunovant, Revolution Medicines and Momenta Pharmaceuticals. Learn More about companies similar to CRISPR Therapeutics.
How do I contact CRISPR Therapeutics' investor relations team?: CRISPR Therapeutics' physical mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company's listed phone number is (141) 561-3277 and its investor relations email address is [email protected]. The official website for CRISPR Therapeutics is www.crisprtx.com. Learn More about contacing CRISPR Therapeutics investor relations.

CRISPR Therapeutics - CRSP Stock Price Target and Predictions

Analyst Price Target for CRSP

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.58 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of CRISPR Therapeutics?

What is the current price target for CRISPR Therapeutics?

What is the current consensus analyst rating for CRISPR Therapeutics?

What other companies compete with CRISPR Therapeutics?

How do I contact CRISPR Therapeutics' investor relations team?